Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Aldevron, Integrated DNA Technologies Enter Agreement | Contract Pharma

What are you searching for?

Sign in
Breaking News

Aldevron, Integrated DNA Technologies Enter Agreement

The agreement is for the provision of a new GMP Cas9 nuclease

By: Betsy Louda

, Contract Pharma

Aldevron and Integrated DNA Technologies have announced a license agreement in which Aldevron will manufacture and distribute a S. pyogenes Cas9 variant (SpyFiTM Cas9 Nuclease), which is patented by IDT. The product will be manufactured for research, clinical, and commercial use.  

 

“IDT continues to be an innovator for the biotechnology industry. We are excited to expand our partnership,” said Michael Chambers, Aldevron’s chief executive officer. “This license will accelerate gene editing programs and help bring transformative treatments to patients.” 

 

An advisory panel at the National Institutes of Health recently approved the first clinical trial using CRISPR-Cas9, which is planned to start by the end of the year. The project uses gene editing to augment cancer therapy by modifying a patient’s T cells. 

 

Aldevron anticipates clinical grade SpyFi Cas9 Nuclease to be available in Q4 2018.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics